The Tumor Necrosis Factor Receptor Superfamily Member 5 pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Necrosis Factor Receptor Superfamily Member 5 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Infectious Disease which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Autoimmune Disorders, Sicca Syndrome (Sjogren), Type 1 Diabetes (Juvenile Diabetes), Diabetes, Infectious Disease, and Chlamydia Infections. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Necrosis Factor Receptor Superfamily Member 5 pipeline targets constitutes close to 52 molecules. Out of which, approximately 49 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 10, 9, 2, 21, and 7 respectively. Similarly, the universities portfolio in Phase II, and Preclinical comprises 1, and 2 molecule.
Tumor Necrosis Factor Receptor Superfamily Member 5 overview
Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.
For a complete picture of Tumor Necrosis Factor Receptor Superfamily Member 5’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
